Biotech: Page 55
-
Peddalanka Ramesh Babu via Getty Images
Pharmas back a startup’s plan to make CAR-T cells inside the body
Capstan Therapeutics was formed by pioneering CAR-T and messenger RNA researchers and has secured funding from five large drugmakers.
By Jonathan Gardner • Sept. 14, 2022 -
Dr_Microbe via Getty Images
MD Anderson launches new spinout to develop radiopharmaceuticals
The joint venture with Radiopharm Theranostics is pursuing a field of research that’s seen a string of recent deals and investments by large drugmakers.
By Kristin Jensen • Sept. 14, 2022 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
vdvornyk via Getty Images
Acelyrin sets hopes high for arthritis drug with $300M fundraise
The well-funded startup is planning Phase 3 trials for a drug it claims could be superior to top-selling medicines from Novartis and others.
By Gwendolyn Wu • Sept. 14, 2022 -
ismagilov via Getty Images
Rubius, a once high-flying biotech startup, lays off much of its staff
The biotech will reduce staff by 75% and end development of two drugs, the latest setback for a company that was worth nearly $2 billion when it went public in 2018.
By Christopher Newman • Sept. 13, 2022 -
Danielle Ternes/BioPharma Dive
BioMarin reports cancer case in hemophilia gene therapy trial
The development comes three weeks after Roctavian was approved in Europe and ahead of a planned regulatory submission in the U.S. Drug regulators have not ordered a trial hold, however.
By Jonathan Gardner • Sept. 13, 2022 -
Permission granted by Third Harmonic
Can biotech IPOs bounce back? Third Harmonic to test investor appetite with planned offering
The startup is the first young drugmaker in more than four months to seek an IPO of at least $100 million, a once common occurrence that's become rare following this year's sector-wide correction.
By Ben Fidler • Sept. 13, 2022 -
Permission granted by Nimbus Therapeutics
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
The money will help fund development of a TYK2 inhibitor that Nimbus CEO Jeb Keiper claims is more selective than Bristol Myers’ Sotyktu.
By Gwendolyn Wu • Sept. 12, 2022 -
Permission granted by Bluebird bio
Bluebird CFO resigns ahead of gene therapy launch
Jason Cole, who replaced former CFO Gina Consylman in March, is leaving six months later to “pursue new career opportunities,” the company said.
By Delilah Alvarado • Sept. 12, 2022 -
Permission granted by Stig Albansson / Pretzel Therapeutics
Mitochondrial drugs, with a twist: Pretzel Therapeutics launches with $72.5M in funding
Scientists at Pretzel believe fixing mutated mitochondrial DNA with a mix of small molecule therapies and gene editing could be key to solving a number of hard-to-treat diseases.
By Gwendolyn Wu • Sept. 12, 2022 -
Permission granted by Gilead Sciences
Gilead says its breast cancer drug helped patients live longer in study
The data could help Trodelvy secure a place in treatment, although a rival drug from Daiichi Sankyo and AstraZeneca will offer strong competition.
By Jonathan Gardner • Sept. 8, 2022 -
Permission granted by Relay Therapeutics
Relay impresses with early study data for targeted cancer drug
Updated data released ahead of the ESMO medical conference suggest Relay’s medicine could be more effective than others like it in treating a type of bile duct cancer.
By Ned Pagliarulo • Sept. 8, 2022 -
Sarah Silbiger via Getty Images
FDA advisers back Amylyx ALS drug, reversing earlier position
Committee members voted 7-2 in support of the experimental medicine, which is under a closely watched FDA review. A decision on approval is expected by the end of the month.
By Jacob Bell • Updated Sept. 7, 2022 -
luismmolina via Getty Images
Backed by Bristol Myers, ArsenalBio raises $220M for its cell therapy research
The biotech’s Series B fundraising equips it with new cash just as it prepares to advance its first drug candidate into clinical testing.
By Delilah Alvarado • Sept. 7, 2022 -
Roche to pay $250M for Good Therapeutics and its targeted drug technology
The team behind the Seattle-based startup will launch a new company, Bonum Therapeutics, after the sale to Roche is completed.
By Kristin Jensen • Sept. 7, 2022 -
Christoph Burgstedt via Getty Images
Beam-linked startup launches with an eye on the next generation of RNA drugs
Orbital co-founder and former Alnylam CEO John Maraganore said the startup aims to “overcome some of the shortcomings that have been there with the first generation of RNA companies.”
By Gwendolyn Wu • Sept. 7, 2022 -
Courtesy of Sarepta
Sarepta to restart Duchenne drug study after FDA lifts hold
The biotech will expand patient monitoring in response to a previously reported serious adverse reaction that had led the FDA in June to suspend testing.
By Ned Pagliarulo • Sept. 6, 2022 -
Christoph Burgstedt via Getty Images
State of PlayDrugging RNA with pills: small molecules for a big frontier
A handful of startups have formed in recent years with plans to target RNA with small molecules. Many have caught the attention of big drugmakers.
By Gwendolyn Wu • Sept. 6, 2022 -
alvarez via Getty Images
Finch to lay off 37% of staff after Takeda ends microbiome drug deal
The company will cut 50 full-time positions and halt preclinical work on a pill for symptoms of autism in its second restructuring effort since April.
By Christopher Newman • Sept. 2, 2022 -
Stock/Ezume Images via Getty Images
With rare acquisition, Novo Nordisk makes $1B bet on sickle cell disease drug
The target company, Forma Therapeutics, started as a developer of cancer drugs but has made the most progress in rare blood disorders, attracting Novo’s attention.
By Jonathan Gardner • Updated Sept. 6, 2022 -
Spencer Platt via Getty Images
Biotech startup Ocean pivots from IPO to SPAC merger
The blank-check deal gives Ocean another route to public markets after it struggled to price an initial public offering it revealed back in June 2021.
By Delilah Alvarado • Aug. 31, 2022 -
SciePro via Getty Images
Jounce’s latest setback dampens outlook for another cancer immunotherapy target
The biotech's drug prospect vopratelimab has become the latest member of a group of medicines targeting a molecule called ICOS to fall short of expectations in clinical testing.
By Jonathan Gardner • Aug. 30, 2022 -
Permission granted by Atlas Venture
Q&A // Emerging biotechAtlas Venture’s Bruce Booth on testing the IPO waters and putting the ‘tech’ in biotech
In a wide-ranging conversation with BioPharma Dive, Booth, a prolific builder of new biotechs, said he’s starting to see positive signs for startups considering an IPO or private financing.
By Gwendolyn Wu • Aug. 30, 2022 -
Permission granted by Akili Inc.
Q&AAkili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment
With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.
By Elise Reuter • Aug. 29, 2022 -
iStock via Getty Images
Takeda ends deal with Finch as bumpy ride continues for microbiome drugs
The pharma company terminated a collaboration that could’ve netted the biotech about $350 million. It’s the latest in a string of recent setbacks for microbiome drug developers.
By Ben Fidler • Aug. 26, 2022 -
Dr_Microbe via Getty Images
ElevateBio finds a new manufacturing home and long-term gene therapy partner in Pittsburgh
The biotech signed a 30-year deal with the University of Pittsburgh to establish a gene and cell therapy manufacturing hub that’s being built with a $100 million grant.
By Kristin Jensen • Aug. 25, 2022
Previous
